Current treatments for malignant gliomas are still largely ineffective in significantly improving prognosis. We have investigated the efficacy of treating established rat C6 glioma by in situ retroviral delivery of IFN-␥ cDNA. Ecotropic retrovirus packaging cells were transfected with a retroviral vector containing the mouse IFN-␥ gene. The IFN-␥ packaging cells were stereotactically implanted into established intracranial C6 glioma in immunocompetent Wistar rats, resulting in the eradication of these tumors. All IFN-␥-treated rats survived to 92 days after C6 implantation (an arbitrary
Introduction
Malignant gliomas are the most common primary neoplasms of the central nervous system. Despite advances made in the diagnosis of malignant glioma and development of different treatment modalities, these tumors remain incurable. Current therapies have not improved the prognosis for patients diagnosed with high-grade glioma (glioblastoma multiforme), which remains less than 1 year. 1 Gliomas are highly heterogeneous and even cells from a single tumor will be of different malignancy grades. Therefore, targeting a single growth factor or receptor expressed by the glioma cells is of limited therapeutic use as a proportion of the tumor cells will escape treatment. Thus, new therapeutic strategies need to be developed for improved long-term management of gliomas.
The approach of cytokine gene therapy, whereby a host-mediated immune response against tumors is elicited, has been widely investigated. Cytokines such as interleukin-2, 2 granulocyte-macrophage colony-stimulating factor 3, 4 and interleukin-12 5 have been demonstrated to have an anti-tumorigenic role in vivo. The expression of specific cytokines by target cells within the tumor can induce and augment an immune response. This response includes the stimulation of lymphocyte proliferation and an increase in the expression levels of the major histocompatibility complex (MHC). We have previously demonstrated that established intracranial rat C6 gliomas are end point) compared with 14 days for controls. Analysis of these treated brains showed that the established C6 tumors had been completely eradicated by this time-point with brain morphology appearing normal. The IFN-␥-mediated tumoricidal activity resulted from an apparent interplay of B and T cell components of the immune system, as well as the inhibition of tumor angiogenesis. This therapeutic strategy may provide an effective method of eradicating established intracranial tumors. Gene Therapy (2000) 7, 1715-1724.
rapidly and completely eradicated by in situ retroviral mouse interleukin-4 (mIL-4) gene therapy. 6 The T cell arm of the immune response and the inhibition of tumor angiogenesis 6, 7 primarily mediate the antitumorigenic activity of mIL-4 therapy. Targeting common pathways such as tumor angiogenesis and the host-mediated immune response, enable the development of therapeutic strategies that overcome the heterogeneity of malignant gliomas. The localized expression of cytokine also overcomes many of the side-effects associated with systemic administration.
In this study, we have investigated the therapeutic potential of interferon-␥ (IFN-␥), a cytokine reported to induce the host-mediated immune response and modulate tumor angiogenesis. IFN-␥ is produced by T lymphocytes that have been stimulated by specific antigens or mitogens. This cytokine can generate an antitumor cellular immune response by directly stimulating CD8
+ cytotoxic T lymphocytes, natural killer cells and macrophages. [8] [9] [10] IFN-␥ can also enhance antigen presentation on tumor cells through increased MHC class I and II expression. [11] [12] [13] Furthermore, IFN-␥ has been noted to modulate tumor angiogenesis by inhibiting endothelial tube formation in vitro. 14 Recombinant IFN-␥ has been used extensively in clinical trials, 15, 16 however, the high doses required to induce an antitumorigenic response resulted in severe systemic side-effects. An alternative approach has been to implant tumor cells or fibroblasts engineered to express IFN-␥ into animal models. These modified cells cause varying levels of tumor regression in several animal tumor models. [17] [18] [19] [20] [21] Another strategy has been to administer purified viruses carrying the IFN-␥ gene directly into tumors. 22, 23 However, multiple administrations of virus were required to induce a tumoricidal response.
We have examined the efficacy of in situ retroviral IFN-␥ therapy on established intracranial C6 gliomas. This approach overcomes the need for systemic administration of IFN-␥ or multiple administrations of purified virus. We have implanted mIFN-␥ retroviral packaging cells (RPCs) directly into established C6 gliomas. The advantage of retroviruses is that they will only integrate their DNA into dividing cells. In the brain, the dividing cells are primarily the tumor cells and the tumorassociated vascular endothelium. The retroviruses we have produced in this and other studies 6, 24, 25 predominantly transduce the proliferating vascular endothelium rather than C6 cells. It is the transduced cells within the tumor mass that produce sustained high levels of IFN-␥ in vivo for a prolonged antitumorigenic response.
We now report the efficacy of treating intracranial gliomas by implanting a single dose of mIFN-␥ RPCs directly into established intracranial gliomas. The expression of IFN-␥ at the site of the tumor results in the complete regression of intracranial tumors. This is due to the inhibition of tumor angiogenesis and the induction of a host-mediated immune response. This treatment strategy does not require multiple administrations and overcomes the side-effects associated with systemic IFN-␥ delivery.
Results

Generation of mIFN-␥ ecotropic retrovirus packaging cell lines
The mIFN-␥ cDNA (a gift from J Boyle, The Walter and Eliza Hall Institute) was cloned into the BglII restriction site of the pZIG retroviral vector 24 ( Figure 1 ). GP+E-86 ecotropic retrovirus packaging cells were transfected with the pZIG(IFN-␥) DNA then were determined to have viral titers ranging between 5 × 10 5 and 2 × 10 6 CFU/ml. NIH 3T3 cells transduced with supernatants from the different GP+E-86/IFN-␥ clones were demonstrated to produce 12-36 ng/ml of mIFN-␥. The two GP+E-86/IFN-␥ clones, 7C and 8F, used in this study both had titers of 2.0 × 10 6 CFU/ml and the transduced NIH 3T3 cells produced 32 and 36 ng/ml mIFN-␥, respectively, in 48 h (see Materials and methods). The shuttle vector alone packaging cell line (SV) 6 had a viral titer of 1.4 × 10 6 CFU/ml and the transduced NIH 3T3 cells did not produce a detectable level of mIFN-␥. The ecotropic retroviruses produced by 7C, 8F or SV did not effectively transduce rat C6 glioma cells in culture (Ͻ80 CFU/ml). 6 Staining for the expression of the ␤-galactosidase marker gene, in C6 tumors implanted with these packaging cell lines, revealed that ecotropic retroviral transduction was specifically targeted to the dividing tumor-associated vascular endothelium and not the C6 cells. 
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The treatment of established C6 tumors in athymic mice with mIFN-␥ retrovirus packaging cells Rat C6 glioma cells were subcutaneously implanted in the flanks of athymic (nu/nu) mice and tumors were clearly palpable 14-16 days later. The GP+E-86/mIFN-␥ retrovirus packaging cell (RPC) lines, 7C and 8F, or the control RPC line, SV, were implanted directly into the tumors and tumor growth was monitored for the duration of the experiments. In the first set of experiments (Figure 2a) , the growth rate of parental C6 tumors or C6 tumors implanted with SV RPCs were similar with mean volumes of 0.34 ± 0.49 (s.e.) cm 3 and 0.29 ± 0.41 (s.e.) cm 3 , respectively, at 24 days after C6 implantation (Figure 2a) . The C6 tumors implanted with the 7C or 8F mIFN-␥ packaging cell lines had a slower growth rate over time in comparison to parental C6 or SV implanted C6 tumors (Figure 2a) . However, the 7C and 8F RPC implanted tumors continued to increase in volume with time. At 24 days after C6 implantation, the 7C and 8F RPC implanted tumors had similar volumes of 0.078 ± 0.02 (s.e.) cm 3 and 0.087 ± 0.016 (s.e.) cm 3 . The mIFN-␥-treated tumors were approximately 25% of the control tumor volumes at this time-point. This result demonstrates that the mIFN-␥- treated tumors grow at a significantly (P Ͻ 0.003) slower rate than control tumors.
The above experiments were repeated with the SV and 8F RPCs to allow long-term monitoring of the tumor growth rates. C6 tumors were palpable at day 14 after implantation and SV RPCs or 8F RPCs were implanted intratumorally. Once again, the mIFN-␥-treated C6 tumors grew at a slower rate than SV control tumors. At 26 days after C6 implantation, the SV-implanted tumors reached a mean volume of 0.68 ± 0.026 (s.e.) cm 3 compared with 0.17 ± 0.03 (s.e.) cm 3 for the mIFN-␥-treated tumors (Figure 2b ). This once again demonstrated that the mIFN-␥-treated tumors were only 25% of the control SV tumor volume (P Ͻ 0.004). Day 26 was the experimental endpoint for the mice with the control SV implanted tumors, whereas the mice with the 8F implanted tumors were monitored further. At day 36 after C6 implantation, the 8F implanted tumors had a mean volume of 0.33 ± 0.072 (s.e.) cm 3 ( Figure 2b ) which is 50% smaller than the volume observed for the SV implanted tumors 10 days earlier. Although the mIFN-␥-treated C6 tumors were growing at a slower rate than controls, their growth was not completely inhibited and they did not exhibit growth arrest or regression within the duration of the experiments.
Histological analysis of subcutaneous C6 tumors in athymic mice
The degree of tumor necrosis and granulocyte infiltrate was determined in control and experimental tumors by staining frozen tumor sections with hematoxylin and eosin. Histological analysis was performed on tumors excised at the experimental endpoint of day 24 after C6 implantation ( Figure 2a The level of tumor vascularization in control and IFN-␥-treated C6 tumors at 24 days after C6 implantation was determined by indirect immunoperoxidase staining of frozen tissue sections with an anti-PECAM monoclonal antibody. The blood vessels were then directly visualized and quantified for each tumor. Parental C6 and SVimplanted tumors had similar levels (14.32 ± 0.77 (s.e.) and 14.02 ± 0.69 (s.e.), respectively) of vascularisation ( Figure 4Aa and Ab). In contrast, there was a significantly reduced level of vascularization in C6 tumors implanted with 7C (11.34 ± 0.53 (s.e.)) or 8F (7.96 ± 0.62 (s.e.)) RPCs (Figure 4Ac and Ad) at this time point. The mean number of vessels observed per standard field was most significantly reduced in 8F-treated tumors (P Ͻ 0.001). Although the 7C-treated tumors were more vascularized than those treated with 8F RPCs, the number of vessels per standard field observed was still significantly lower than in controls (P Ͻ 0.005). In addition to a reduced number of vessels in the IFN-␥-treated C6 tumors, differ- Treatment of established intracranial C6 tumors in immunocompetent rats by mIFN-␥ retrovirus packaging cells Rat C6 glioma cells were stereotactically implanted into immunocompetent Wistar rat brains and tumors were allowed to establish. Previous histological analysis of rat brains at 7 days after C6 implantation revealed that the tumors had reached a volume of 6.44-6.79 mm 3 . 6 At this time-point, either SV or 8F RPCs were stereotactically implanted into the rat brains at the same site as the C6 cells were previously implanted. Rats were allowed to recover and the experiments were continued until signs of discomfort or lethargy were observed in the rats. By 14 days after C6 implantation (7 days after RPC implantation), all of the rats bearing parental C6 tumors and those implanted with SV RPCs showed signs of lethargy and poor health and it was therefore determined to be the end-point for both control groups. In contrast, the experimental rats implanted with 8F RPCs did not show any signs of deteriorating health. Thus, experimental rats were continued for a longer period of time. In each experiment, four of the eight rats in the experimental group were culled at day 14 after C6 implantation in order for histological analysis to be performed at the same time-point as the control rats. All of the 8F-implanted experimental rats remained healthy and active for a significantly longer period of time, so 92 days after C6 implantation (85 days after mIFN-␥ treatment) was determined to be the arbitrary end-point for the experimental group to enable histological analysis to be performed. Even at this end-point, the mIFN-␥-treated rats demonstrated a dramatic increase in survival compared with parental or SV-implanted rats (92 days compared with 14 days).
Histological analysis of the control and experimental rat brains at 14 days after C6 implantation revealed a difference in the 8F-implanted C6 tumor volume compared with controls ( Figure 5 ). The mean tumor volume of parental C6 and SV-implanted tumors were not significantly different (P Ͻ 0.429) ( Figure 5 ). The mean volume of C6 tumors implanted with 8F RPCs was 50% less than SVimplanted and parental C6 tumor volumes (Figures 5 and  6) . However, the level of significance (P Ͻ 0.248) of tumor inhibition is reduced by the variation of 8F-treated tumor volumes. Brains of 8F-treated rats that were culled at the arbitrary end-point of 92 days (after C6 implantation) were also subjected to histological analysis for the presence of C6 tumors. Tumors appeared to have completely regressed with an area of necrosis present at the site of C6 implantation ( Figure 6 ). Tumor cells were not detected either at the primary site of implantation or at a secondary site as the brains were sectioned in their entirety.
The inflammatory response induced by retroviral mIFN-␥ therapy of intracranial rat C6 tumors
The inflammatory response associated with the IFN-␥-mediated anti-tumorigenic activity was examined in
Figure 3 Photomicrographs of hematoxylin and eosin-stained subcutaneous rat C6 tumor sections (from athymic mice) following implantation of SV control or mIFN-␥ (7C or 8F) RPCs. Tumor analysis was performed at 24 days after C6 implantation. (a) Parental C6 tumor demonstrating 10-15% necrosis (× 100); Established C6 tumor implanted with (b) SV RPCs showing similar levels of necrosis as parental C6 control tumors (× 100). (c) mIFN-␥ 7C RPCs demonstrating an increased level of tumor necrosis compared with controls (× 100). (d) mIFN-␥ 8F RPCs also with an increased level of tumor necrosis compared with controls (× 10). (e-h) Higher magnification photomicrographs of a-d (× 600). An increase in the macrophage and granulocyte infiltrate is evident in mIFN-␥-treated C6 tumors compared with controls.
brains at 14 days after C6 implantation. Hematoxylin and eosin staining of brain tumor tissue revealed a high level of macrophage and granulocyte infiltration in 8F-treated tumors ( Figure 7 ) compared with C6 and SV controls. This result correlates with the level of infiltrate seen in the subcutaneous tumors ( Figure 3) . The control and SV RPC-implanted tumors did not express mIFN-␥ ( Figure  7a ). In contrast, mIFN-␥ expression was demonstrated in 8F-treated tumors, particularly in the tumor-associated vascular endothelium of vessels in and around the tumor margin (Figure 7b) .
Parental C6 and SV-implanted tumors did not express the rat homologue of MHC class I (Table 1, Figure 7e ). Low levels of MHC class I expression were observed in the SV-implanted tumors. Similar expression levels of the rat homologue of MHC class II were seen in both parental C6 and SV-implanted tumors (Table 1, Figure 7c ). The expression of MHC class II was observed mainly within the tumor mass and surrounding blood vessels. Some normal brain cells immediately surrounding the tumor also expressed MHC class II. Increases in both MHC class I and class II expression levels were observed in C6 tumors implanted with 8F RPCs (Table 1) . MHC class I expression was limited to the C6 tumor mass and to blood vessels within and surrounding the tumor ( Figure  7f ) and not in normal brain cells at a distance from the tumor. An increase in MHC class II expression was also observed in the 8F-implanted tumors compared with controls ( Table 1 ). The increase in MHC class II expression was detected within the primary tumor mass, with a greater increase observed in the vessels and normal brain cells surrounding the tumor (Figure 7d ). The normal brain cells expressing MHC class II antigen were detected a short distance away from the tumor mass, but were rarely observed in the contralateral hemisphere. Thus, the local expression of mIFN-␥ at the tumor site resulted in an increase of MHC class I and class II expression on tumor cells and tumor-associated vessels.
Indirect immunoperoxidase staining with a panel of monoclonal antibodies was used to differentiate the different T cell populations infiltrating the tumor sites (Table 1) . At day 14, C6 and SV control tumors had a very low number of CD4 + cells within the tumor. In addition to CD4
+ cells, SV-treated tumors were infiltrated with CD8 + T cells. In contrast, the 8F-treated tumors had a very high level of CD4 + , CD8
+ and CD3 + cells infiltrating the tumors and the normal brain tissue immediately surrounding the tumor (Figure 8) . A large number of macrophages was also observed in and around the tumor margin (Figure 8 ). Macrophages, CD4
+ and CD8 + T cells were also detected around clusters of C6 cells that had migrated a short distance away from the primary tumor site (data not shown). Thus, IFN-␥ expression induced a Gene Therapy 
Figure 6 Hematoxylin and eosin staining of frozen rat brain sections following the implantation of established C6 tumors with mIFN-␥ RPCs. Brains were analyzed at 14 days after C6 implantation (7 days after implantation of RPCs). (a) C6 tumor implanted with SV RPCs; (b and c) C6 tumor implanted with the mIFN-␥ RPCs, 8F; (d) C6 tumor implanted with 8F RPCs in rat brains at 92 days after C6 implantation (× 200). Arrow denotes tumor margin.
T cell-mediated immune response against the tumor cells, that is required for complete tumor regression.
Discussion
The cellular and molecular heterogeneity of gliomas requires the development of treatment protocols that target broadly based biological pathways essential for the growth and progression of all gliomas. Two such systems are tumor angiogenesis and the host immune response. Therapeutic protocols that simultaneously inhibit tumor angiogenesis and elicit a host-mediated immune response against the tumor should have greater tumoricidal activity in vivo. A number of cytokines have been reported to have both anti-angiogenic and immunogenic properties. Our studies demonstrating the complete
Figure 7 The expression of rat major histocompatibility (MHC) class I and II and IFN-␥ in C6 tumors implanted with IFN-␥ RPCs. Indirect immunoperoxidase staining of intracranial parental C6 tumors (day 14) for the expression of: (a) mIFN-␥ (× 200); (c) RT1.B (rat MHC class II homologue) (× 100); (e) RT1.A (rat MHC class I homologue) (× 100). Immunoperoxidase staining of intracranial C6 tumors implanted with 8F RPCs (day 14 after C6 implantation, day 7 after 8F implantation): (b) mIFN-␥ (× 200); (d) RT1.B (× 100); (f) RT1.A (× 100).
eradication of C6 intracranial tumors by in situ retroviral mIL-4 transfer illustrated the therapeutic potential of single cytokines with multiple biological targets. 6 We now report the efficacy of treating established intracranial C6 gliomas in rats by in situ retroviral mIFN-␥ gene transfer.
The therapeutic properties of IFN-␥ against certain classes of tumors have been established for many years. However, the systemic administration of the high doses of IFN-␥ required to produce a tumoricidal response in clinical trials resulted in severe side-effects. Hence, alternative delivery systems were sought to enable the expression of high local concentrations of IFN-␥ at the site of the tumor to allow eradication without the associated side-effects. Initial studies engineered tumor cell lines to express IFN-␥ then implanted them into animal models as primary tumors 20 or to treat tumor metastases.
21,26
The development of virus-based gene therapy techniques enabled herpes simplex virus type 1-defective virus 22 or retrovirus 23 to be engineered to express IFN-␥ and implanted into primary tumors. Enhanced tumor rejection was observed when multiple administrations of high 
/TcR monoclonal antibody (453(MCA)); (d) mouse anti-rat macrophage monoclonal antibody (ED1) (× 100).
titer retrovirus (10 8 CFU/ml daily for 7 days) were injected intratumorally. 23 Similar findings were reported in a phase I clinical trial for the treatment of patients with metastatic melanoma administered IFN-␥ retrovirus. 27 In order to overcome the need for multiple administrations of IFN-␥ retrovirus, we have examined the efficacy of implanting the IFN-␥ RPCs directly into established C6 tumors.
The implantation of mIFN-␥ RPCs into established subcutaneous C6 tumors in athymic nu/nu mice, resulted in a slower rate of tumor growth compared with controls. However, the tumors did not demonstrate growth arrest or regression, which supported previous reports in immunocompromised models. 20 Histological analysis revealed large areas of necrosis in mIFN-␥-treated tumors. This necrosis may be due to the high level of macrophage and granulocyte infiltration and the significantly reduced degree of vascularization observed. Blood vessels were also smaller in size and had thinner vessel walls after IFN-␥ treatment. The blood vessels were visualized in our study using immunohistochemical staining for PECAM (CD31) expression on vascular endothelial cells. Several studies have addressed the role of IFN-␥ in the regulation of PECAM expression on cultured endothelial cells. However, these results varied widely. [28] [29] [30] Staining serial sections of IFN-␥-treated tumors with antibodies that detect PECAM or Factor VIII-related antigen produced identical results. 25 Thus, IFN-␥ did not appear to alter the staining pattern of PECAM expression in our C6 tumor model. The quanti-fication of vessels in tumors visualized by PECAM staining was therefore confirmed by staining for Factor VIIIrelated antigen. 25 The mechanism of IFN-␥ regulation of tumor vascularization remains unclear. Studies are now underway to examine the role of this cytokine in tumor angiogenesis in vitro and in vivo. IFN-␥ has been shown to inhibit tube formation of HUVEC cells in vitro. 14 The possibility of this occurring in IFN-␥-treated C6 tumors in vivo is now being investigated and may explain the smaller vessel structures observed. The IFN-␥-mediated inhibition of tumor angiogenesis may also result from induction of chemokine expression such as IFN-␥ inducible protein-10 (IP-10) and monokine induced by IFN-␥ (Mig). 31, 32 Both IP-10 and Mig are C-X-C chemokines and are potent angiostatic factors. 33, 34 The expression of IP-10 and Mig in IFN-␥-treated C6 tumors is currently being analyzed. Despite the increased necrosis, granulocyte and macrophage infiltrate and reduced tumor vascularization, the IFN-␥-treated subcutaneous tumors continued to grow although at a slower rate. The combination of these antitumor responses in immunocompromised mice was not sufficient to induce tumor growth arrest or regression.
Intracranial C6 gliomas established in immunocompetent rats were stereotactically implanted with mIFN-␥ RPCs and analyzed 7 days later. Varying levels of tumor regression were observed in individual rats at this timepoint. In some brains, the tumors were completely eradicated with only a small necrotic site and an immune infiltrate apparent at the implantation site. In other brains, the tumors had continued to grow after treatment, but were largely necrotic and had an increased granulocyte infiltrate. The reason for the variation in the degree of tumor regression observed is not clear. The immune competence levels of the individual rats may contribute to tumor rejection rates observed in mIFN-␥-treated rats. Despite the variation in tumor regression observed 7 days after mIFN-␥ treatment, the C6 tumors had completely regressed in all brains by 85 days after mIFN-␥ treatment (92 days after C6 implantation). An enhanced tumoricidal response may be observed if a higher dose of IFN-␥ RPCs is implanted into the C6 tumors, or if a higher titer packaging cell line is used. As this ecotropic retrovirus does not effectively transduce C6 cells, retroviral transduction was targeted to the dividing vascular endothelium. 6 Hence, the use of amphotropic retrovirus which also targets tumor cells may result in a higher in situ transduction rate, a higher level of IFN-␥ expression, and subsequently, a more rapid tumoricidal response. In our current treatment model, C6 tumors were still completely eradicated in all rat brains following IFN-␥ treatment and there was no evidence of tumor at this time-point.
Analysis of rat brains 7 days after mIFN-␥ RPC treatment revealed a strong up-regulation of the rat homologues for MHC class I and class II. This increase in expression was limited to C6 tumor cells and the tumorassociated vessels and was not apparent in normal brain. IFN-␥-treated tumors were highly infiltrated with CD8 + and CD4
+ T lymphocytes and macrophages compared with control tumors. These results suggest that activation of the T cell arm of the immune response is essential for tumor regression.
A recent study has reported that adenoviral IFN-␥ gene transfer into established 3LL glioma cells resulted in the Gene Therapy suppression of tumor growth in vivo by the inhibition of tumor angiogenesis. 35 In this study, 1.5 × 10 3 3LL cells were implanted subcutaneously or intracranially into syngeneic mice. These cells were allowed to establish for 2 days before implantation of adenovirus-IFN-␥ cells. A significant increase in survival of mice (30-40%) was observed following adenovirus-IFN-␥ cell implantation. Similar survival data were derived from treatment of tumors in scid or beige C57BL/6 mice. Histological analysis of treated tumors revealed an inhibition of tumor angiogenesis and an increase in apoptosis of endothelial cells. In addition, neovascularization of 3LL cells in vivo was inhibited when they were admixed with adenovirus IFN-␥ cells in a matrigel assay. 35 Our data support these results as we have also demonstrated an inhibition of tumor angiogenesis in vivo.
In contrast to our data, however, adenovirus-IFN-␥-mediated tumor inhibition did not involve an immune response. 35 In this study by Fathallah-Shaykh et al, 35 adenovirus-IFN-␥ treatment was initiated on very small tumors (1.5 × 10 3 cells established for 2 days) compared with the large established tumors in our study (10 6 for subcutaneous implantation established for 14-16 days, or 10 5 cells for intracranial implantation established for 7 days). An inhibition of angiogenesis alone may be sufficient to inhibit tumor growth when tumors are small and just beginning to establish their vasculature. In contrast, when tumors are larger and have an established vascular bed, the inhibition of angiogenesis would only stop further vascular expansion. We have demonstrated that IFN-␥ treatment of established C6 tumors in athymic mice leads to a slower tumor growth rate, but is not sufficient to inhibit completely growth. Interestingly, when 3LL cells were subcutaneously co-implanted with adenovirus-IFN-␥ cells, tumor growth was suppressed for 2 weeks, but tumors were clearly palpable after 3 weeks. 35 Gene transfer experiments performed on larger, wellestablished tumors should be more representative of tumors treated clinically. Our results suggest that the eradication of large established C6 tumors by IFN-␥ treatment require an induction of the host-mediated immune response.
Several different pathways mediate the antitumorigenic activity of IFN-␥ in our therapy model. IFN-␥ expression inhibits tumor angiogenesis, which results in a slowing down of tumor growth rate. Intratumoral expression of IFN-␥ also mediates an up-regulation of MHC class I and class II expression on tumor cells and elicits an immune infiltrate consisting of macrophages, neutrophils, CD8
+ and CD4 + T lymphocytes. The combination of these activities contributes to active tumor eradication. The requirement for a T cell response does not preclude retroviral IFN-␥ transfer from being effective clinically. Glioma patients can experience varying levels of T cell suppression. However, this suppression is not complete and only occurs for transient periods, particularly following surgery and corticosteroid therapy. The reduction of glioma growth would be an advantage in controlling tumor size during this period until a full immune response is mounted. mIFN-␥ was predominantly expressed by vascular endothelial cells of vessels within the tumors and at the tumor margin in mIFN-␥-treated tumors. Similarly, there was no evidence of retroviral transduction in the contralateral hemisphere as determined by ␤-galactosidase expression (data not shown). These results demonstrate that mIFN-␥ expression is localized at the site of the tumor, and that the associated immune response is limited to the tumor and the tumor margin. The immune cells induced by mIFN-␥ treatment are not present in normal brain tissue at a distance from the primary tumor site. Thus, the localized production of mIFN-␥ elicits a specific antitumorigenic response without affecting normal brain tissue.
We have demonstrated that in situ retroviral therapy is an effective method for delivering a high local concentration of IFN-␥ to an established tumor, resulting in complete tumor regression. The advantages of this protocol for the treatment of gliomas are: (1) the complete regression of tumors using a single administration of IFN-␥ RPCs; (2) cytokine expression and subsequent immune and anti-angiogenic responses are localized to the tumor and not normal brain tissue; (3) the targeting of common biological pathways (the host immune response and tumor angiogenesis) overcomes the heterogeneity of gliomas and improves therapeutic efficacy; (4) tumor regression is dependent on the expression of a high local concentration of IFN-␥ rather than on an extremely high transduction frequency rate as required for suicide gene therapy protocols. 36 These properties suggest that this therapeutic strategy may be an effective treatment for other solid tumors in addition to gliomas.
Further studies are now being conducted to determine if rats treated with IFN-␥ RPCs are immune to subsequent C6 challenge. A CD8 + T cell-mediated immune memory response would suggest that tumor regrowth or growth at a secondary site would be rejected. Hence, long-term protection would be possible with a single administration of IFN-␥ therapy. Amphotropic mIFN-␥ retroviral packaging cell lines are also being generated to improve the C6 tumor transduction frequencies in animal models. This study demonstrates the therapeutic potential of IFN-␥ as a treatment for glioma and the advantage of the in situ retroviral gene transfer strategy. This strategy is being further developed for future clinical trials as a primary therapy or as an adjuvant therapy for gliomas.
Materials and methods
Cell culture
The rat C6 glioma cell line was obtained from American Type Culture Collection (ATCC), Rockville, MD, USA (ATCC CCL 107), and were cultured as previously described. 37 The ecotropic retroviral packaging cell line GP+E-86 6, 38 and NIH 3T3 cells (ATCC CCL 163) were also cultured as previously described. 24, 39 Packaging cells and retroviral infected NIH 3T3 cells resistant to geneticin G418 (Life Technologies, Melbourne, Australia) were selected and maintained in medium supplemented with this antibiotic at concentrations of 1 and 0.4 mg/ml of medium, respectively.
mIFN-␥ retroviral construct
The details of the pZIG(SV) retroviral vector have been previously reported. 24 The mouse IFN-␥ cDNA (550 bp coding region) 40 was excised from pBluescript as a SalI/NotI insert then blunt ended with Klenow DNA Polymerase I (Promega, Madison, WI, USA). The IFN-␥ cDNA was ligated to BglII linkers before cloning into the BglII restriction site of the pZIG(SV) vector located upstream of the IRES element (Figure 1 ). The ␤geo marker gene incorporated as the 3Ј cistron in the pZIG(SV) vector, encodes a fusion protein for neomycin-resistance and ␤-galactosidase. 41 Restriction mapping and nucleotide sequencing were used to confirm the correct orientation of the IFN-␥ cDNA in pZIG(IFN-␥).
Isolation of retrovirus producing GP+E-86 clones Transfection of the GP+E-86 ecotropic retroviral packaging cells (RPCs) 38 with the pZIG(IFN-␥) DNA was performed using Lipofectamine Plus (Life Technologies) reagent according to the manufacturer's protocol. GP+E-86 cells were also transfected with pZIG(SV) DNA (a retrovirus control plasmid that lacks a cytokine gene) by calcium phosphate transfection as previously described. 39 The resultant transfected GP+E-86/IFN-␥ RPCs (7C or 8F) or control GP+E-86/SV RPCs (SV) were selected in complete culture medium supplemented with 1 mg/ml G418. Individual G418-resistant packaging clones were grown to subconfluency and dilutions of the cell-free supernatants were used to transduce NIH 3T3 cells as previously described 24 and selected in 0.4 mg/ml G418 in order to determine viral titers. Transduced NIH 3T3 (10 6 ) clones were cultured for 48 h in normal medium and supernatants were tested by ELISA (R&D Systems, Minneapolis, MN, USA) for mIFN-␥ production. The expression of ␤-galactosidase by transfected packaging cells and infected NIH 3T3 cells was detected as previously described. 24 Subcutaneous tumor analysis Adult female athymic (nu/nu) mice were subcutaneously implanted with 10 6 C6 cells in 100 l of serum-free culture medium. Tumor volumes were determined every second day by tridimensional calliper measurements (length × width × depth (cm 3 )) for the duration of the experiments. Fourteen days after implantation, when tumors were clearly palpable, 10 6 SV, 7C or 8F RPCs in 100 l of serum-free medium were implanted directly into the established subcutaneous C6 tumors. The tumor sizes of six tumors per cell line (one tumor per mouse) were calculated. Each experiment was performed in triplicate. Histological analysis was carried out on tumors excised at the end of each experiment. A Student's t test (paired, unequal variance) was used to calculate the significance of tumor growth rates of parental C6 tumors and SV or IFN-␥-treated tumors.
Intracranial tumor analysis
Adult female Wistar rats were anesthetized and 10 5 rat C6 glioma cells (resuspended in 10 l of serum-free cell culture medium) were implanted stereotactically into the brain through the coronal suture left of the midline to a depth of 3 mm. Seven days after implantation, the procedure was repeated with 10 6 SV control RPCs or 8F mIL-4 RPCs stereotactically implanted directly into the tumor and the incision closed. This experiment was performed on eight rats per group in three sets of experiments. Brains were analyzed histologically at day 14 or 92 days after C6 implantation and tumor volumes were calculated as length × width × depth (mm 3 ). A Student's t test (paired, unequal variance) was used to calculate the level of significance of the tumor growth rates derived from parental C6 tumors and SV or IFN-␥-treated tumors.
Histological analysis of tissue
Serial frozen sections (7 m) of subcutaneous tumor or whole brain were stained in the following ways: (1) hematoxylin and eosin for tumor cell volumes and infiltrating granulocytes; (2) indirect immunoperoxidase with the rat anti-mouse PECAM monoclonal antibody (MAB) (PharMingen, San Diego, CA, USA) or mouse anti-rat PECAM MAB (Endogen, Woburn, MA, USA) for vascular endothelial cells in mouse 7, 37, 42 or rat 43, 44 tissue respectively; (3) indirect immunoperoxidase with the mouse anti-rat RT1.B class II MAB (HIS 19; Serotec, Oxford, UK), the mouse anti-rat RT1.A MHC class I MAB (Ox-18; Serotec), the rat anti-mouse IFN-␥ MAB (XMG1-2), the mouse anti-rat CD3 + /TcR MAB (453(MCA)), the mouse anti-rat CD4 + MAB (W3/25), the mouse anti-rat CD8 + MAB (Ox8) or the mouse anti-rat macrophage MAB (ED1) (gifts from P Motram, The University of Melbourne); (4) ␤-galactosidase staining for visualization of RPC and transduced cells. 24 Vascular density was calculated by counting the number of vessels in 10 random standard fields (0.55 × 0.4 mm) in five sections per tumor. A Student's t test (paired, unequal variance) was used to calculate the level of significance of the number of vessels observed in control C6 and SV-treated tumors and IFN-␥-treated tumors.
